BMO Capital Maintains Outperform on AbbVie, Lowers Price Target to $180

AbbVie, Inc. +3.59%

AbbVie, Inc.

ABBV

175.27

+3.59%

BMO Capital analyst Evan David Seigerman maintains AbbVie (NYSE: ABBV) with a Outperform and lowers the price target from $195 to $180.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via